Business Context and Reporting Period
This Form 6-K filing by James Hardie Industries Plc covers the month of February 2018, with the report signed on February 14, 2018. The registrant is a foreign private issuer headquartered in Dublin, Ireland, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of a substantial shareholder event and contains forward-looking statement disclosures rather than a financial results report.
Material Changes
The primary material event disclosed in this filing is a Substantial Shareholder Notification dated February 13, 2018 (Exhibit 99.1). The filing text does not detail the specific nature or magnitude of the shareholding change.
Guidance, Outlook, and Risks
The document contains an extensive list of forward-looking statements and associated risks. Key areas of uncertainty and risk identified include:
- Asbestos Liabilities: Contributions to the Asbestos Injuries Compensation Fund (AICF), potential shortfalls, and currency exchange impacts on recorded liabilities.
- Legal and Regulatory: Product liability, environmental matters, intellectual property, and competition law proceedings.
- Market Conditions: Dependence on US and Asia Pacific housing markets, new home construction levels, and consumer confidence.
- Operational Risks: Costs related to plant closures or capital expenditure projects, raw material supply, and the integration of the Fermacell acquisition.
- Financial Risks: Currency exchange rates, credit facility renewals, and tax law changes.
Key Facts for Investor Verification
- Verify the details of the Substantial Shareholder Notification referenced in Exhibit 99.1 to understand the specific change in ownership.
- Review the most recent Form 20-F or quarterly earnings release for actual financial performance metrics, as this 6-K does not contain them.
- Monitor updates regarding the Asbestos Injuries Compensation Fund (AICF) and any changes in required contributions.
- Assess the status of the Fermacell acquisition integration and associated capital expenditure plans.